The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.
A prospective study found that patients who underwent vNOTES hysterectomy recovered bowel function and returned to work faster than those who had traditional laparoscopic surgery.
Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.
Patients with atypical Alzheimer’s variants had shorter survival and faced a 31% higher mortality risk than those with typical forms, according to a study of over 2,000 biomarker-confirmed cases.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A new breast reconstruction technique using the superficial branch of the SCIA flap showed safe outcomes in 4 women, offering an alternative to DIEP flaps with less abdominal trauma.
In a 72-week study of hepatitis B patients, researchers found liver stiffness declines were driven by improved inflammation, not actual fibrosis regression.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.